Research Projects & Grants

  • Randomized clinical trial assessing the effects of Pneumatic Vitreolysis on Vitreomacular traction (Protocol AG), Role: PI, (07/2019 - 07/2020) Status: Completed
  • Single-arm study assessing the effects of Pneumatic Vitreolysis on Macular Hole (Protocol AH), Role: PI, Status: Completed

Federal

  • Genetics in retinal diseases project, Role: Investigator, National Eye Institute/NIH/DHHS, (10/2024 - 10/2025) Status: Approved
  • Intravitreous Anti-VEGF treatment for prevention of vision threatening diabetic retinopathy in eyes at high risk, Role: Investigator, National Eye Institute/NIH/DHHS, (04/2022 - 04/2023) Status: Completed
  • Randomized trial of Intravitreous Aflibercept versus Intravitreous Bevacizumab + deferred Aflibercept for treatment of central-involved diabetic macular edema (Protocol AC), Role: Investigator, National Institute on Minority Health and Health Disparities/NIH/DHHS, Status: Completed
  • Vitreous Proteomics in Eyes with a Macular Hole (Protocol AJ), Role: PI, Jaeb Center for Health Research, Status: Completed
  • A phase 2 Evaluation of Tonabersat for Diabetic Macular Edema (Protocol AN), Role: Investigator, Jaeb Center for Health Research, Status: Completed

For Profit Organization

  • A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD), Role: Investigator, NGM Biopharmaceuticals, Inc., (10/2022 - 10/2023) Status: Completed
  • A 64-week, two-arm, randomized, double-masked, multi-center, phase IIIb study assessing the efficacy and safety of Brolucizumab 6 mg compared to Aflibercept 2 mg in a treat-to-control regimen in patients with neovascular age-related macular degeneration (TALON), Role: Investigator, Novartis Pharmaceuticals Corporation, (08/2022 - 08/2023) Status: Completed
  • A 12-Month, 2-Arm, randomized, double-masked, multicenter Phase III study assessing the efficacy and safety of Brolucizumab every 4 weeks versus Aflibercept every weeks in adult patients with visual impairment due to Diabetic Macular Edema (KINGFISHER), Role: Investigator, Novartis Pharmaceuticals Corporation, (09/2020 - 09/2021) Status: Completed
  • A Phase 2b multicenter dose-ranging study evaluating the safety and efficacy of a Long-acting Intravitreal Sunitinib Malate Depot Formulation (GB-102) compared to Intravitreal Aflibercept in subjects with Neovascular (Wet) Age-related Macular Degeneration (ALTISSIMO study), Role: Investigator, Graybug Vision, Inc., (09/2020 - 08/2021) Status: Completed
  • Protocol AJ – Vitreous Proteomics in Eyes with a Macular Hole, Role: PD/PI, Diabetic Retinopathy Clinical Research Network (DRCRnet), (08/2020 - 03/2025) Status: Closed
  • A phase 2/3, randomized, double-masked, sham-controlled trial of QPI-1007 delivered by single or multi-dose intravitreal injection(s) to subjects with acute nonarteritic anterior ischemic optic neuropathy (NAION), Role: Investigator, Quark Pharmaceuticals, (01/2019 - 01/2020) Status: Completed
  • A 24-week, double-masked, multicenter, two-arm extension study to collect safety and efficacy data on brolucizumab 6 mg drug product intended for commercialization in patients with neovascular age-related macular degeneration who have completed the CRTH258A2301 study, Role: Investigator, Novartis Pharmaceuticals Corporation, (07/2018 - 07/2019) Status: Completed

Internal

  • Retrospective Analysis of Incidence, Prevalence, and Treatment Modalities of Neurotrophic Keratitis Post-Retinal Procedures, Role: PI, LLU Dept. of Ophthalmology, (08/2023) Status: Approved
  • Retrospective study of Visual Outcomes after Sutured Posterior Chamber Intraocular lens, Role: PI, LLU Dept. of Ophthalmology, (06/2022) Status: Approved
  • Collection of vitreous and aqueous samples from patient undergoing vitrectomy and intravitreal injections, Role: PI, LLU Dept. of Ophthalmology, (03/2020) Status: Approved

Non-Profit Organization

  • Intravitreous anti-VEGF vs. prompt vitrectomy for vitreous hemorrhage from proliferative diabetic retinopathy (protocol AB), Role: Investigator, National Institute for Health Care Management Research and Educational Foundation, (03/2020 - 03/2021) Status: Completed